CombiANT: clinical antibiotic interactions diagnostic
| Reference number | |
| Coordinator | Rx Dynamics AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | November 2022 - September 2023 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Impact Startups autumn 2022 |
Purpose and goal
In this project we had 2 major objectives 1.Conduct a comprehensive BETA test within the academic realm, and 2.Execute rigorous clinical validation of the assay tailored for the healthcare sector.
Expected effects and result
We´ve achieved pivotal milestones this past year. Our BETA test across diverse academic institutions received strong positive feedback, leading to its extension. This progress, coupled with deepened collaborations with six major academic labs across Europe, underlines our product´s growth and adaptability. Embracing AI, we´re evolving towards "hands-off automation." With our strategic branding efforts in 2022, we´ve amplified our digital presence. The clinical validation that started in 2023 is expected to undergo independant review early 2024.
Planned approach and implementation
CombiANT made landmark progress. We collaborated with top academic labs across Europe for a BETA test, refining our software based on invaluable feedback. Our product also underwent rigorous validation with the help of the University Hospital of Lausanne, reinforcing its promise for healthcare. With Vinnova´s support, we accelerated our market entry, merging academia and clinical diagnostics, setting new industry standards.